keyword
MENU ▼
Read by QxMD icon Read
search

Lymphocytopenia, cancer

keyword
https://www.readbyqxmd.com/read/27766953/impaired-telomere-maintenance-in-alazami-syndrome-patients-with-larp7-deficiency
#1
Brody Holohan, Wanil Kim, Tsung-Po Lai, Hirotoshi Hoshiyama, Ning Zhang, Anas M Alazami, Woodring E Wright, M Stephen Meyn, Fowzan S Alkuraya, Jerry W Shay
BACKGROUND: Loss of function in genes required for telomere maintenance result in disorders known as telomeropathies, which are characterized by a pattern of symptoms including generalized and specific lymphocytopenias as well as very short telomere length and disease anticipation. METHODS: Because human LARP7 is the most likely ortholog of the Tetrahymena p65 protein, which is required for telomerase activity in that organism, we investigated the effects of LARP7 silencing in human cells as well as in two distinct families with Alazami syndrome (loss of function of LARP7)...
October 17, 2016: BMC Genomics
https://www.readbyqxmd.com/read/27674808/a-higher-integral-heart-dose-is-associated-with-lymphocytopenia-in-non-small-cell-lung-cancer-patients-treated-with-intensity-modulated-radiation-therapy-and-concurrent-chemotherapy
#2
N Joseph, A McWilliam, J Kennedy, C Faivre-Finn, A Choudhury
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27484254/a-retrospective-study-of-predictive-factors-for-unexpectedly-prolonged-or-shortened-progression-free-survival-and-overall-survival-among-patients-with-metastatic-renal-cell-carcinoma-who-received-first-line-targeted-therapy
#3
Sung Han Kim, Sohee Kim, Jungnam Joo, Ho Kyung Seo, Jae Young Joung, Kang Hyun Lee, Jinsoo Chung
BACKGROUND: To identify predictors of prolonged or shortened progression-free survival (PFS) and overall survival (OS) among patients with metastatic renal cell carcinoma (mRCC) who received first-line targeted therapies. METHODS: This retrospective study included 146 patients with mRCC who were treated during 2007-2015. These patients were divided into a group with the worst response (WG), an expected group (EG), and a group with the best response (BG), based on their PFS (≤3 monthsnths, 3-18 monthsnths, and >18 monthsnths, respectively) and OS (<1 year, 1-3 years, and >3 years, respectively)...
2016: BMC Cancer
https://www.readbyqxmd.com/read/27471640/identification-of-a-novel-human-memory-t-cell-population-with-the-characteristics-of-stem-like-chemo-resistance
#4
Kenji Murata, Tomohide Tsukahara, Makoto Emori, Yuji Shibayama, Emi Mizushima, Hiroshi Matsumiya, Keiji Yamashita, Mitsunori Kaya, Yoshihiko Hirohashi, Takayuki Kanaseki, Terufumi Kubo, Tetsuo Himi, Shingo Ichimiya, Toshihiko Yamashita, Noriyuki Sato, Toshihiko Torigoe
High-dose chemotherapy may kill not only tumor cells but also immunocytes, and frequently induces severe lymphocytopenia. On the other hand, patients who recover from the nadir maintain immunity against infection, suggesting the existence of an unknown memory T-cell population with stress resistance, long-living capacity, proliferation and differentiation. Recently, the differentiation system of T-cell memory has been clarified using mouse models. However, the human T-cell memory system has great diversity induced by natural antigens derived from many pathogens and tumor cells throughout life, and profoundly differs from the mouse memory system constructed using artificial antigens and transgenic T cells...
June 2016: Oncoimmunology
https://www.readbyqxmd.com/read/27029035/prognostic-models-to-predict-survival-in-patients-with-advanced-non-small-cell-lung-cancer-treated-with-first-line-chemo-or-targeted-therapy
#5
Rossana Berardi, Silvia Rinaldi, Matteo Santoni, Thomas Newsom-Davis, Michela Tiberi, Francesca Morgese, Miriam Caramanti, Agnese Savini, Consuelo Ferrini, Mariangela Torniai, Ilaria Fiordoliva, Marc Bower, Stefano Cascinu
BACKGROUND: We aimed to assess the prognostic role of neutrophilia, lymphocytopenia and the neutrophil-to-lymphocyte ratio (NLR), and to design models to define the prognosis of patients receiving first-line chemo- or targeted therapy for advanced non-small cell lung cancer (NSCLC). MATERIALS AND METHODS: We retrospectively analysed 401 consecutive patients with advanced NSCLC treated with first line chemo- or targeted therapy. Patients were stratified into two groups with pre-treatment NLR ≥ 3...
May 3, 2016: Oncotarget
https://www.readbyqxmd.com/read/26842789/phase-i-ii-study-of-nab-paclitaxel-plus-gemcitabine-for-chemotherapy-naive-japanese-patients-with-metastatic-pancreatic-cancer
#6
MULTICENTER STUDY
Hideki Ueno, Masafumi Ikeda, Makoto Ueno, Nobumasa Mizuno, Tatsuya Ioka, Yasushi Omuro, Takako Eguchi Nakajima, Junji Furuse
PURPOSE: Efficacy and safety of nab-paclitaxel plus gemcitabine have not been clarified in Japanese patients with metastatic pancreatic cancer. No pharmacokinetic profile of co-administration of nab-paclitaxel and gemcitabine has been reported. We conducted a phase I/II study of the efficacy, safety, and pharmacokinetics in Japanese patients with metastatic pancreatic cancer. METHODS: The patients were administered 125 mg/m(2) nab-paclitaxel followed by 1000 mg/m(2) gemcitabine on day 1, 8, and 15 every 4 weeks...
March 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/26489581/-a-case-of-esophageal-cancer-in-a-patient-with-cmv-reactivation-after-neoadjuvant-chemoradiation-therapy
#7
Koichi Megumi, Hiroshi Okumura, Masataka Shimonosono, Tetsuya Ijichi, Yasuto Uchikado, Itaru Omoto, Hiroyoshi Yo, Yoshiaki Kita, Yoshikazu Uenosono, Takaaki Arigami, Shinichiro Mori, Kenji Baba, Sumiya Ishigami, Tetsuhiro Owaki, Shoji Natsugoe
A68 -year-old woman was diagnosed with advanced esophageal cancer with lymph node metastasis, for which she received neoadjuvant chemoradiotherapy. During therapy, she had loss of appetite and weight; therefore, we inserted a nasal feeding tube for her nutrition, after which, she gained weight soon. After therapy, she had a high fever with lymphocytopenia and was diagnosed with cytomegalovirus infection because of significantly high CMV antigenemia. Ganciclovir was administered immediately, and she recovered soon...
October 2015: Gan to Kagaku Ryoho. Cancer & Chemotherapy
https://www.readbyqxmd.com/read/26372098/pretreatment-immune-parameters-predict-for-overall-survival-and-toxicity-in-early-stage-non-small-cell-lung-cancer-patients-treated-with-stereotactic-body-radiation-therapy
#8
Narek Shaverdian, Darlene Veruttipong, Jason Wang, Dorthe Schaue, Patrick Kupelian, Percy Lee
INTRODUCTION: We determined whether pretreatment immunologic parameters could predict the outcomes and toxicity in early-stage non-small-cell lung cancer (NSCLC) patients treated with stereotactic body radiation therapy (SBRT). PATIENTS AND METHODS: The pretreatment leukocyte, lymphocyte, and neutrophil counts, serum albumin levels, neutrophil-to-lymphocyte ratio (NLR,) and platelet-to-lymphocyte ratio (PLR) were evaluated to determine the association with locoregional control, distant metastasis-free survival (DMFS), disease-specific survival (DSS), overall survival (OS), and treatment-related toxicity...
January 2016: Clinical Lung Cancer
https://www.readbyqxmd.com/read/25772149/wilms-tumor-1-peptide-vaccination-combined-with-temozolomide-against-newly-diagnosed-glioblastoma-safety-and-impact-on-immunological-response
#9
Naoya Hashimoto, Akihiro Tsuboi, Naoki Kagawa, Yasuyoshi Chiba, Shuichi Izumoto, Manabu Kinoshita, Noriyuki Kijima, Yoshihiro Oka, Soyoko Morimoto, Hiroko Nakajima, Satoshi Morita, Junichi Sakamoto, Sumiyuki Nishida, Naoki Hosen, Yusuke Oji, Norio Arita, Toshiki Yoshimine, Haruo Sugiyama
To investigate the safety of combined Wilms tumor 1 peptide vaccination and temozolomide treatment of glioblastoma, a phase I clinical trial was designed. Seven patients with histological diagnosis of glioblastoma underwent concurrent radiotherapy and temozolomide therapy. Patients first received Wilms tumor 1 peptide vaccination 1 week after the end of combined concurrent radio/temozolomide therapy, and administration was continued once per week for 7 weeks. Temozolomide maintenance was started and performed for up to 24 cycles, and the observation period for safety encompassed 6 weeks from the first administration of maintenance temozolomide...
June 2015: Cancer Immunology, Immunotherapy: CII
https://www.readbyqxmd.com/read/25700774/phase-i-study-of-lapatinib-and-pemetrexed-in-the-second-line-treatment-of-advanced-or-metastatic-non-small-cell-lung-cancer-with-assessment-of-circulating-cell-free-thymidylate-synthase-rna-as-a-potential-biomarker
#10
COMPARATIVE STUDY
Rodryg Ramlau, Michael Thomas, Silvia Novello, Ruth Plummer, Martin Reck, Tomomi Kaneko, Mike R Lau, Jane Margetts, John Lunec, Joyce Nutt, Giorgio V Scagliotti
INTRODUCTION: Lapatinib is a dual tyrosine kinase inhibitor that targets epidermal growth factor receptor and HER2. We report on a dose-escalation study of lapatinib combined with pemetrexed in second-line treatment to evaluate the safety and efficacy in advanced or metastatic non-small-cell lung cancer (NSCLC) and an exploratory study in which circulating cell-free thymidylate synthase ribonucleic acid (cfTSmRNA) was measured in all patients and compared with clinical benefit. PATIENTS AND METHODS: Eligible patients had stage IIIB or IV NSCLC after 1 previous line of chemotherapy and an Eastern Cooperative Oncology Group performance status of 0 to 2...
September 2015: Clinical Lung Cancer
https://www.readbyqxmd.com/read/25592632/sunitinib-in-patients-with-chemotherapy-refractory-thymoma-and-thymic-carcinoma-an-open-label-phase-2-trial
#11
MULTICENTER STUDY
Anish Thomas, Arun Rajan, Arlene Berman, Yusuke Tomita, Christina Brzezniak, Min-Jung Lee, Sunmin Lee, Alexander Ling, Aaron J Spittler, Corey A Carter, Udayan Guha, Yisong Wang, Eva Szabo, Paul Meltzer, Seth M Steinberg, Jane B Trepel, Patrick J Loehrer, Giuseppe Giaccone
BACKGROUND: No standard treatments are available for advanced thymic epithelial tumours after failure of platinum-based chemotherapy. We investigated the activity of sunitinib, an orally administered tyrosine kinase inhibitor. METHODS: Between May 15, 2012, and Oct 2, 2013, we did an open-label phase 2 trial in patients with histologically confirmed chemotherapy-refractory thymic epithelial tumours. Patients were eligible if they had disease progression after at least one previous regimen of platinum-containing chemotherapy, an Eastern Cooperative Oncology Group performance status of two or lower, measurable disease, and adequate organ function...
February 2015: Lancet Oncology
https://www.readbyqxmd.com/read/25573268/radium-223-dichloride-a-novel-treatment-option-for-castration-resistant-prostate-cancer-patients-with-symptomatic-bone-metastases
#12
REVIEW
Shane McGann, Evan R Horton
OBJECTIVE: To review and evaluate the clinical trial efficacy and safety of radium 223 ((223)Ra) along with its place in therapy in men with castration-resistant prostate cancer (CRPC). DATA SOURCES: A literature search in PubMed/MEDLINE (up to October 2014) was performed using various combinations of the terms radium, hormone-refractory prostate cancer, and castration-resistant prostate cancer. The New Drug Application Medical, Pharmacology, and Clinical Pharmacology and Biopharmaceutics Reviews for radium (223)Ra dichloride were also utilized...
April 2015: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/25171214/lymphocytopenia-induced-by-vinorelbine-doxorubicin-and-cisplatin-in-human-cancer-patients
#13
Taha Nazir, Azharul Islam, Muhammad Ovais Omer, Mazhar Mustafa
Cancer chemotherapy exerts deleterious effects in patients, causing structural and physiological changes to their vital organs. These drugs are capable of destroying bone marrow cells and may reduce lymphocyte count. This study was aimed to investigate the frequency of lymphocytopenia in cancer patients taking vinorelbine and its combination as part of cancer chemotherapy. A total 60 adult cancer patients were selected and divided into two groups; Group-1 patients were either on Vinorelbine alone treatment protocol, while group 2 patients were on either Vinorelbine/Cisplatin or Vinorelbine/Doxorubicin treatment protocol...
2015: Breast Disease
https://www.readbyqxmd.com/read/25164472/cost-of-adverse-events-during-treatment-with-everolimus-plus-exemestane-or-single-agent-chemotherapy-in-patients-with-advanced-breast-cancer-in-western-europe
#14
Mario Campone, Hongbo Yang, Elizabeth Faust, Andrew Kageleiry, James E Signorovitch, Jie Zhang, Haitao Gao
OBJECTIVE: Treatment options for recurrent or progressive hormone receptor-positive (HR+) advanced breast cancer include chemotherapy and everolimus plus exemestane (EVE + EXE). This study estimates the costs of managing adverse events (AEs) during EVE + EXE therapy and single-agent chemotherapy in Western Europe. METHODS: An economic model was developed to estimate the per patient cost of managing grade 3/4 AEs for patients who were treated with EVE + EXE or chemotherapies...
December 2014: Journal of Medical Economics
https://www.readbyqxmd.com/read/24875133/a-phase-i-study-of-decitabine-with-pegylated-interferon-%C3%AE-2b-in-advanced-melanoma-impact-on-dna-methylation-and-lymphocyte-populations
#15
E R Plimack, J R Desai, J P Issa, J Jelinek, P Sharma, L M Vence, R L Bassett, J L Ilagan, N E Papadopoulos, W J Hwu
BACKGROUND: Melanoma cell lines treated with decitabine show upregulation of cancer antigens, and interferon-α upregulates MHC Class I antigens in cancer cells, leading to enhanced T-cell recognition and T-cell mediated tumor apoptosis. We evaluated the synergy between the hypomethylating effects of decitabine and the immunomodulatory effects of interferon in a combination regimen administered to advanced melanoma patients in a phase 1 trial. METHODS: Patients with one prior systemic therapy were eligible...
October 2014: Investigational New Drugs
https://www.readbyqxmd.com/read/24327130/respiratory-syncytial-virus-infections-in-children-with-cancer
#16
Roy F Chemaly, Shashank S Ghantoji, Dimpy P Shah, Jharna N Shah, Katia K El Taoum, Richard E Champlin, Cesar A Nunez, Victor Mulanovich, Ella Ariza-Heredia
Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract infections (LRTIs) in children, especially those with cancer. Data on RSV infections in this vulnerable population is limited. We conducted a retrospective study of all RSV infections in children with cancer from 1998 to 2009 to determine characteristics and outcomes of these infections, identify risk factors for LRTI and mortality, and the effect of antiviral therapy on these outcomes. We identified 59 patients with a median age of 5 years; 53% had hematologic malignancy, 32% were hematopoietic stem cell transplant recipients, 39% had received corticosteroids, and 76% cytotoxic chemotherapy within 1 month before RSV infection...
August 2014: Journal of Pediatric Hematology/oncology
https://www.readbyqxmd.com/read/24190979/radium-ra-223-dichloride-injection-u-s-food-and-drug-administration-drug-approval-summary
#17
RANDOMIZED CONTROLLED TRIAL
Paul G Kluetz, William Pierce, V Ellen Maher, Hui Zhang, Shenghui Tang, Pengfei Song, Qi Liu, Martin T Haber, Eldon E Leutzinger, Ali Al-Hakim, Wei Chen, Todd Palmby, Elleni Alebachew, Rajeshwari Sridhara, Amna Ibrahim, Robert Justice, Richard Pazdur
On May 15, 2013, the U.S. Food and Drug Administration (FDA) approved radium Ra 223 dichloride (Ra-223; Xofigo injection; Bayer HealthCare Pharmaceuticals Inc.) for the treatment of patients with castration-resistant prostate cancer (CRPC), symptomatic bone metastases, and no known visceral metastatic disease. The FDA review was based on clinical trial BC1-06, which randomly allocated patients (2:1) to either Ra-223 plus best standard of care (BSoC) or placebo plus BSoC. The primary endpoint was overall survival (OS) with a key secondary endpoint of time to first symptomatic skeletal event (SSE)...
January 1, 2014: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/24072436/ncic-ctg-ind-181-phase-i-study-of-at9283-given-as-a-weekly-24-hour-infusion-in-advanced-malignancies
#18
S F Dent, K A Gelmon, K N Chi, D J Jonker, N Wainman, C A Capier, E X Chen, J F Lyons, L Seymour
PURPOSE: AT9283 is a potent inhibitor of the mitotic regulators, Aurora-kinases A and B, and has shown anti-tumor activity in patients with solid and haematological malignancies. This phase I study assessed safety, tolerability, pharmacokinetic and pharmacodynamic properties of AT9283. PATIENTS AND METHODS: Patients with advanced, incurable solid tumors or non-Hodgkin's lymphoma received AT9283 as a continuous 24-hour infusion on days 1, 8 of a 21-day cycle. A 3 + 3 dose escalation design was used with a starting dose of 1...
December 2013: Investigational New Drugs
https://www.readbyqxmd.com/read/24019126/reduction-in-radiation-induced-lymphocytopenia-by-famotidine-in-patients-undergoing-radiotherapy-for-prostate-cancer
#19
RANDOMIZED CONTROLLED TRIAL
Abolfazl Razzaghdoust, Hossein Mozdarani, Bahram Mofid, S Mahmoud R Aghamiri, Amir H Heidari
BACKGROUND: Ionizing radiation causes a series of hematological alterations especially profound lymphocytopenia during and after the radiotherapy course. To investigate whether famotidine can reduce hematologic toxicity in patients treated with radiotherapy for prostate cancer. METHODS: A total of 36 patients undergoing radiotherapy for prostate cancer were randomized to receive either placebo or famotidine tablets. Participants were pretreated with 40 mg of oral famotidine or placebo tablets twice daily, 4 and 3 hr before each radiotherapy fraction...
January 2014: Prostate
https://www.readbyqxmd.com/read/23907204/temozolomide-added-to-whole-brain-radiotherapy-in-patients-with-multiple-brain-metastases-of-non-small-cell-lung-cancer-a-multicentric-austrian-phase-ii-study
#20
RANDOMIZED CONTROLLED TRIAL
Marco Ronald Hassler, Wolfgang Pfeifer, Thomas Hendrik Knocke-Abulesz, Klaus Geissler, Gabriele Altorjai, Karin Dieckmann, Christine Marosi
BACKGROUND: This multicentric randomized phase II study investigated the feasibility and toxicity of temozolomide (TMZ) added to whole brain radiotherapy (WBRT) followed by adjuvant TMZ in patients with multiple brain metastases of non-small-cell lung cancer (NSCLC). METHODS: Patients with multiple brain metastases from NSCLC aged ≥ 18 years, classified according to recursive partitioning analysis class I or II and with adequate organ functions were eligible. Treatment consisted of WBRT + TMZ 75 mg/m² for 2 weeks followed at day 28 by TMZ 100 mg/m²/day 2 weeks on/2 weeks off for up to 6 months (radiochemotherapy, RCT) or WBRT alone (radiotherapy, RT)...
August 2013: Wiener Klinische Wochenschrift
keyword
keyword
83156
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"